{"id":4002,"date":"2025-03-31T18:11:55","date_gmt":"2025-03-31T18:11:55","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/flupentixol-txt\/"},"modified":"2025-03-31T18:11:55","modified_gmt":"2025-03-31T18:11:55","slug":"flupentixol-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/flupentixol-txt\/","title":{"rendered":"Flupentixol.txt"},"content":{"rendered":"

Flupentixol <\/h1>\n

CLINICAL USE <\/H3>
\nAntipsychotic:Schizophrenia and other psychoses Depression

DOSE IN NORMAL RENAL FUNCTION <\/H3>Psychosis: Oral: 3\u20139 mg twice daily \u2014Deep IM: 50 mg 4 weekly \u2013 300 mg 2 \u2014weekly; maximum dose 400 mg weekly; 20\u201340 mg every 2\u20134 weeks may be adequate in some patientsDepression: 0.5\u20133 mg daily (doses above 2 mg should be in 2 divided doses, and 2nd dose should not be after 4 pm)

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :434.5 (588.8 as decanoate)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>95<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : Negligible<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :12\u201314<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :22\u201336 (IM: 3\u20138 days)\/Increased

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Start with quarter to half of the dose and titrate slowly

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Alcohol: enhanced effects\n
  • Anaesthetics: enhanced hypotensive effects\n
  • Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids\n
  • Antidepressants: increased plasma level of tricyclics\n
  • Anti-epileptics: anticonvulsant effect antagonised\n
  • Antimalarials: avoid concomitant use with artemether\/lumefantrine\n
  • Antipsychotics: avoid concomitant use of clozapine with depot preparations in case of neutropenia\n
  • Antivirals: concentration possibly increased with ritonavirAnxiolytics and hypnotics: increased sedative effects\n
  • Sibutramine: increased risk of CNS toxicity \u2013 avoid concomitant useAvoid concomitant use with drugs that prolong the QT interval

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral, IM

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>May cause hypotension and sedation in renal impairmentIncreased CNS sensitivity in renally impaired patients \u2013 start with small doses as can accumulateFor IM injection a 20 mg test dose should first be givenOral bioavailability is 40\u201355% Peak levels occur 7 days after IM injection and 4 hours after oral administration.
    \n","protected":false},"excerpt":{"rendered":"

    Flupentixol CLINICAL USE Antipsychotic:Schizophrenia and other psychoses Depression DOSE IN<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4002","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4002","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4002"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4002\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4002"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4002"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4002"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}